Gastro Guideline Reviews
Welcome to our illustrated guideline podcast
Review of the AGA Guideline: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
Guideline Elevator Pitch
The new ulcerative colitis guidelines mark a decisive shift in how we approach the disease. Diagnosis continues to rest on endoscopic evaluation, but clinicians are now urged to combine non-invasive biomarkers like fecal calprotectin and CRP with colonoscopy findings in a treat-to-target framework.
The treatment philosophy has moved away from the traditional step-up model; instead, early use of biologics or small molecules is recommended in patients with moderate to severe disease, with sequencing tailored to comorbidities and patient profile rather than a rigid hierarchy of drugs. Corticosteroids are firmly relegated to short-term bridge therapy, with budesonide MMX favored for milder flares, underscoring the push toward steroid-sparing regimens.
The therapeutic target is not just symptom relief but also endoscopic mucosal healing, highlighting the importance of objective measures of remission. Special attention is given to vulnerable groups: biologics can be safely continued in pregnancy, pediatric patients may warrant early escalation to protect growth, and treatment in the elderly demands a careful balance of efficacy against infection and malignancy risks.
Finally, surgical referral should not be delayed until crisis situations arise but should be integrated as a proactive option in refractory disease or dysplasia.
In short, these guidelines redefine UC care as early, personalized, and goal-directed, with a clear mandate to minimize steroids and pursue durable remission through a treat-to-target approach.